In a study involving 12 patients with bladder cancer, who also underwent prostate surgery as part of their treatment, she identified the ICOS molecule as the first
immunologic marker identified in both tumor tissues and the systemic circulation that can be used as a biomarker for monitoring of anti-CTLA-4 treated patients as a possible marker of therapeutic
activity.